KPIs & Operating Metrics(New)

Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue EBIAT Gross Profit Leases Long-Term Debt Issuances Long-Term Debt Repayments Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Receivables - Other Shares Issued Shares Outstanding Shares Outstanding

Aquestive Therapeutics (AQST) Shares Issued (2017 - 2026)

Aquestive Therapeutics has reported Shares Issued over the past 8 years, most recently at $1.2 million for Q4 2025.

For Q4 2025, Shares Issued rose 73.79% year-over-year to $1.2 million; the TTM value through Dec 2025 reached $1.3 million, up 73.5%, while the annual FY2025 figure was $1.3 million, 73.5% up from the prior year.
Shares Issued for Q4 2025 was $1.2 million at Aquestive Therapeutics, up from $43000.0 in the prior quarter.
Over five years, Shares Issued peaked at $9.9 million in Q1 2021 and troughed at -$24.4 million in Q4 2021.
A 5-year average of $150666.7 and a median of $702000.0 in 2024 define the central range for Shares Issued.
On a YoY basis, Shares Issued climbed as much as 9717.74% in 2021 and fell as far as 39266.13% in 2021.
Year by year, Shares Issued stood at -$24.4 million in 2021, then skyrocketed by 84.55% to -$3.8 million in 2022, then surged by 101.03% to $39000.0 in 2023, then soared by 1700.0% to $702000.0 in 2024, then soared by 73.79% to $1.2 million in 2025.
Business Quant data shows Shares Issued for AQST at $1.2 million in Q4 2025, $43000.0 in Q3 2025, and $7000.0 in Q2 2025.